The radiotherapy treatment comes from an electrical machine called a ‘Linear accelerator’ and is directed as a beam to the part of the body that needs to be treated. Treatment is given daily over a period of days or weeks and you may hear people call these treatments ‘fractions’. They are just a fraction of your treatment dose and plan.
Immunotherapy is a biological therapy and type of targeted treatment that boosts the patient’s natural defence, the immune system, and enables it to find and destroy cancer cells found in the body. At Rutherford Cancer Centres, we use several different types of immunotherapy in the treatment of cancer, in order to prevent cells growing and replicating or spreading around the body.
Chemotherapy at the Rutherford takes place in our modern therapy suites, consisting of up to ten treatment areas offering treatment for haematology/oncology patients requiring systemic anti-cancer therapy (SACT) and supportive care in an outpatient setting. The infusion therapy suites are available for patients undergoing treatment for breast, urology, upper and lower gastrointestinal cancers, and both malignant and non-malignant haematology disorders.
Professor Roger Taylor is a Consultant Clinical Oncologist specialising in the treatment of patients with brain tumours and lymphoma. Professor Taylor was born and educated in Swansea, and trained in Medicine at University College, Oxford and St Bartholomew’s Hospital Medical College. His oncology training was at the Royal Marsden Hospital, Royal London Hospital and Western General Hospital, Edinburgh.
He worked as a Consultant Clinical Oncologist in Leeds from 1987-2006, specialising mainly in the treatment of children with cancer. Professor Taylor returned to Wales in 2006, to work in the South West Wales Cancer Centre, Singleton Hospital, Swansea and the College of Medicine, Swansea University.
Professor Taylor provides specialist advice on proton radiotherapy in Wales, and currently is undertaking research in this field. He is author of many papers on the treatment of children with cancer, particularly brain tumours.
Oncology Vice-President, Royal College of Radiologists 2014-2016
Children’s Cancer and Leukaemia Group (CCLG).
Professor Roger Taylor does not hold a share or financial interest in the Rutherford Cancer Centres or another Proton Partners International company.
Professor Roger Taylor does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Proton Partners International company.
Professor Roger Taylor does hold a paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Proton Partners International.